K. Luijtens

发表

Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial

D. M. van der Heijde, V. Strand, R. Landewé, 2008, Annals of the rheumatic diseases.

Rheumatoid arthritis - treatment 180. Utility of Body Weight Classified Low-Dose Leflunomide in Japanese Rheumatoid Arthritis

Stanley B. Cohen, D. Symmons, M. Dougados, 2011 .

Correlation between Oxidized Low Density Lipoproteins and von Willebrand Factor in Chronic Renal Failure

E. Lesaffre, Y. Vanrenterghem, J. Arnout, 1996, Thrombosis and Haemostasis.

Sustained efficacy of certolizumab pegol added to methotrexate in the treatment of rheumatoid arthritis: 2-year results from the RAPID 1 trial.

N. Goel, D. M. van der Heijde, V. Strand, 2012, Rheumatology.

American College of Rheumatology hybrid analysis of certolizumab pegol plus methotrexate in patients with active rheumatoid arthritis: Data from a 52‐week phase III trial

D. Felson, V. Strand, M. Weinblatt, 2011, Arthritis care & research.

Certolizumab Pegol Efficacy Across Methotrexate Regimens: A Pre‐Specified Analysis of Two Phase III Trials

N. Goel, D. M. van der Heijde, D. Furst, 2016, Arthritis care & research.

Twenty-eight-week results from the REALISTIC phase IIIb randomized trial: efficacy, safety and predictability of response to certolizumab pegol in a diverse rheumatoid arthritis population

M. Dougados, D. M. van der Heijde, P. Emery, 2015, Arthritis Research & Therapy.

Predicting future response to certolizumab pegol in rheumatoid arthritis patients: Features at 12 weeks associated with low disease activity at 1 year

A. Kavanaugh, J. Curtis, K. Luijtens, 2012, Arthritis care & research.

Timing and Magnitude of Initial Change in Disease Activity Score 28 Predicts the Likelihood of Achieving Low Disease Activity at 1 Year in Rheumatoid Arthritis Patients Treated with Certolizumab Pegol: A Post-hoc Analysis of the RAPID 1 Trial

D. M. van der Heijde, R. Landewé, D. Furst, 2012, The Journal of Rheumatology.

Dose escalation of certolizumab pegol from 200 mg to 400 mg every other week provides no additional efficacy in rheumatoid arthritis: an analysis of individual patient-level data.

N. Goel, J. Curtis, M. Weinblatt, 2011, Arthritis and rheumatism.

The growth of the extramatrical mycelium of ectomycorrhizal fungi and the growth response of Pinus sylvestris L.

J. Colpaert, K. Luijtens, J. V. Assche, 1992 .

SAT0084 Effects of different steroid doses on adverse events and radiographic progression of certolizumab pegol-treated rheumatoid arthritis patients

K. Luijtens, E. Keystone, M. Champsaur, 2013 .

Two Dosing Regimens of Certolizumab Pegol in Patients With Active Rheumatoid Arthritis

B. Devellis, B. Gandek, R. Devellis, 2015, Arthritis care & research.

AB0480 Certolizumab pegol plus methotrexate is similarly effective in active rheumatoid arthritis regardless of prior TNF inhibitor use: Analysis of the doseflex PHASE IIIB study

M. Schiff, K. Luijtens, D. Furst, 2013 .

Muscle disorders111. The impact of fatigue in patients with idiopathic inflammatory myopathy: a mixed method study

R. Moots, P. Salkovskis, Yulia Goryachev, 2012 .